Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells

Cancer Letters
Saar ShapiraOfer Shpilberg

Abstract

In this study we present the effects of nilotinib and dasatinib on telomerase activity and regulation. Nilotinib and dasatinib strongly reduced telomerase activity in BCR-ABL-positive (K562) and BCR-ABL-negative (HL60) cells, demonstrating that their effect on telomerase activity is uncoupled from their effect on BCR-ABL. Nilotinib and dasatinib caused a substantial decrease in hTERT mRNA expression. Phospho-Sp1 regulates hTERT transcription. We detected a considerable decrease in Sp1 nuclear expression and binding to the hTERT promoter following exposure to the drugs. We also detected a reduction in Map kinase, known to phosphorylate Sp1. Telomerase is also activated and translocated to the nucleus when phosphorylated by AKT. We detected a decrease in phospho-AKT and a reduction in the nuclear expression of hTERT following exposure to nilotinib and dasatinib. In conclusion, we provide evidence for transcriptional and post-translational inhibition of telomerase by nilotinib and dasatinib which is not necessarily mediated via known targets of these tyrosine kinase inhibitors.

References

Jan 1, 1992·Annual Review of Biochemistry·E H Blackburn
Jun 1, 1996·Molecular and Cellular Biology·S E HoltJ W Shay
Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·X ZhuR Narayanan
Feb 21, 1997·Cell·T F FrankeL C Cantley
Jul 25, 1997·Science·B A Hemmings
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·S E HoltW E Wright
Nov 10, 1998·International Journal of Cancer. Journal International Du Cancer·T KanayaM Inoue
Jul 15, 1999·International Journal of Cancer. Journal International Du Cancer·T W ParkF Jänicke
Jul 11, 2001·The Journal of Biological Chemistry·R ChenY Qiu
Jan 16, 2002·Current Opinion in Genetics & Development·Dara L AisnerJerry W Shay
Aug 9, 2002·International Journal of Oncology·L BoldriniG Fontanini
Sep 5, 2002·Microbiology and Molecular Biology Reviews : MMBR·Yu-Sheng CongJerry W Shay
Feb 26, 2003·The Journal of Biological Chemistry·Tianyun Jiang, Yun Qiu
Apr 22, 2005·Critical Reviews in Oncology/hematology·Carolyn K DongWilliam C Hahn
Jun 25, 2005·Current Molecular Medicine·Oliver G Opitz
Jan 18, 2006·Biochemical and Biophysical Research Communications·Yumiko MatsubaraYasuo Ikeda
Feb 3, 2006·Journal of Cellular Physiology·Lunyu KuoWen-Chun Hung
Jun 16, 2006·The New England Journal of Medicine·Hagop KantarjianOliver G Ottmann
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
May 25, 2007·Nature Reviews. Cancer·Junia V Melo, David J Barnes
Jul 20, 2007·The New England Journal of Medicine·Charles A Schiffer
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Seiichi OkabeKazuma Ohyashiki
Jul 2, 2009·Clinical and Experimental Pharmacology & Physiology·Julie M Dwyer, Jun-Ping Liu
Aug 25, 2010·Annals of Anatomy = Anatomischer Anzeiger : Official Organ of the Anatomische Gesellschaft·Oumar SamassekouJu Yan
Nov 19, 2010·Molecular Biology Reports·Aneta WojtylaBlazej Rubis
Jun 15, 2011·Expert Review of Hematology·Amber FullmerElias Jabbour

❮ Previous
Next ❯

Citations

Sep 24, 2013·Journal of Medicinal Chemistry·Vijay SekaranMichael B Jarstfer
Apr 28, 2016·Pharmacology & Therapeutics·Yinnan Chen, Yanmin Zhang
Jul 28, 2016·Genes·Kathrin Jäger, Michael Walter
May 24, 2016·Current Opinion in Hematology·Claudia Bruedigam, Steven W Lane
Oct 27, 2020·Scandinavian Journal of Gastroenterology·Stine K OversoeJens Kelsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.